RxDoctor Payments Data

Manuel Lopez, MD

Otolaryngology/Facial Plastic Surgery · San Antonio, TXNPI 1770505984

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 69.0% of it on its own, with 6 other manufacturers making up the rest. Among otolaryngology/facial plastic surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$55,221in general payments, 2019–2025

Across 376 payments — averaging $146.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$38K
  • Lumenis BE Inc$14K
  • Galderma Laboratories, L.p.$2K
  • Merz North America, Inc.$495
  • Revance Therapeutics, Inc.$228
  • Ardelyx, Inc.$63
  • plus $48 from 1 others

What the payments were for

  • Consulting fees$1,0002%
  • Speaking & faculty fees$29,41253%
  • Travel & lodging$1,5563%
  • Food & beverage$23,25342%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,221 in reported general payments places this provider in the 95th percentile of 51 otolaryngology/facial plastic surgery providers in Texas.

See all otolaryngology/facial plastic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$51,574
Medicare patients
107
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina11$6,677
ValacyclovirValacyclovir Hcl75$1,339
Mupirocin125$898
Prednisolone Acetate27$765
ErythromycinErythromycin Base73$764
Cephalexin122$737
Aprepitant11$426
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen32$348
Ibuprofen28$241
Tramadol Hcl79$230
Clindamycin Hcl19$111
Methylprednisolone13$110
Alprazolam32$103
Promethazine Hcl15$49
Clonidine Hcl33$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$38,078$6,67711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 otolaryngology/facial plastic surgery providers in Texas.

Other otolaryngology/facial plastic surgery in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →